| coronary artery disease | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Nishimura, 2009 | nicorandil vs control | | | |
| Trial | Treatments | Patients | Method |
|---|
| Nishimura, 2009 | nicorandil 15 mg daily (n=-9) vs. control (n=-9) | Maintenance hemodialysis patients who underwent percutaneous coronary artery intervention and had complete coronary revascularization (absence of both restenosis and de novo coronary lesion) at coronary arteriography 6 months later | open Parallel groups Sample size: -9/-9 Primary endpoint: cardiac death FU duration: 2.7 years |
|
| percutaneous coronary intervention | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Nishimura, 2009 | nicorandil vs control | | | |
| Trial | Treatments | Patients | Method |
|---|
| Nishimura, 2009 | nicorandil 15 mg daily (n=-9) vs. control (n=-9) | Maintenance hemodialysis patients who underwent percutaneous coronary artery intervention and had complete coronary revascularization (absence of both restenosis and de novo coronary lesion) at coronary arteriography 6 months later | open Parallel groups Sample size: -9/-9 Primary endpoint: cardiac death FU duration: 2.7 years |
|
